• Viravaxx closes Series A investment round

    Vienna, Jan. 17, 2017 Viravaxx AG, an emerging biopharmaceutical company focussed on the development of antiviral vaccines for difficult to treat virus infections as well as diagnostic products for the detailed analysis of the immunological response to virus infections, announced today the closing of private financing round in the amount of €4.22 million. Participating in | read more »

    read more »